Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2002

View Archived Issues

New data reported for minodronic acid in the treatment of osteolysis and osteoporosis

Potential use of AMG-073 for treating cancer-related hypercalcemia

Pharmacokinetic data reported for extended-release lovastatin

Olpadronate found to promote BMD increase in children with osteogenesis imperfecta

INS-365, a mucin stimulant, effective in a rabbit model of dry eye syndrome

Potential use of Doxil in the treatment of mesothelioma

PEG-rHuMGDF reported to be effective in chronic ITP

Neuroprotective effects reported for minocycline in rat pups

Effects of resveratrol on human myeloid leukemia cell lines

New modulators of immunotherapeutic agents described by Altachem and U. of Alberta

Shionogi describes the isolation of IL-12 production inhibitor from plant

GSK designs new series of Tie2 inhibitors

Novel cannabinoid ligands identified by U.S. university researchers

NCI awards SPORE grant for lymphoma research

Helivax to enter phase II Helicobacter trials

Enzon acquires North American rights to Abelcet

GPC Biotech to codevelop satraplatin with NeoTherapeutics

Roche seeks additional indication for Bondronat in E.U.

Fast track status for tariquidar in NSCLC

Taxoprexin phase III program proceeds

Cephalon reacquires rights to Actiq in key European markets

11-Substituted macrolide and ketolide antibiotics with activity against ERY-resistant bacteria

AC98-6446: a new semisynthetic glycopeptide antibiotic with excellent Gram-positive activity

Small-molecule HCV therapeutics sought in Enanta-Chiron collaboration

ICAAC abstract details mechanism of action, effects in murine model of GVHD for PNP inhibitor

Bristol-Myers Squibb patent covers novel factor Xa inhibitors

Inhibitors of voltage-gated potassium channels in the ICAgen pipeline

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026